<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 16. Mean Pharmacokinetic Parameters in Pediatric Subjects With Epilepsy 
			</caption>
<tfoot>
<tr>
<td align="justify" colspan="5">
<sup>a</sup> Carbamazepine, phenytoin, phenobarbital, and primidone have been shown to increase the apparent clearance of lamotrigine. Estrogen-containing oral contraceptives, rifampin, and the protease inhibitors lopinavir/ritonavir and atazanavir/ritonavir have also been shown to increase the apparent clearance of lamotrigine <content stylecode="italics">[see <linkhtml href="#Section_7">Drug Interactions (7)</linkhtml>]</content>.<br/>
<sup>b</sup> Two subjects were included in the calculation for mean T<sub>max</sub>.<br/>
<sup>c  </sup>Parameter not estimated.<br/>
</td>
</tr>
</tfoot>
<tbody>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Pediatric Study Population</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">Number of</content>
<br/>
<content stylecode="bold"> Subjects</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">T<sub>max</sub>
</content>
<br/>
<content stylecode="bold">(h)</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">t<sub>½</sub>
</content>
<br/>
<content stylecode="bold">(h)</content>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">
<content stylecode="bold">CL/F</content>
<br/>
<content stylecode="bold">(mL/min/kg)</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Ages 10 months to 5.3 years</content>
<br/> <br/> Subjects taking carbamazepine,<br/> phenytoin, phenobarbital, or<br/> primidone<sup>a</sup>
<br/> <br/> Subjects taking AEDs with no<br/> known effect on the apparent<br/> clearance of lamotrigine<br/> <br/> Subjects taking valproate only <br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>10<br/> <br/> <br/> <br/>7<br/> <br/> <br/> <br/>8<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>3<br/>(1 to 5.9)<br/> <br/> <br/>5.2<br/>(2.9 to 6.1)<br/> <br/> <br/>2.9<br/>(1 to 6)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>7.7<br/>(5.7 to 11.4)<br/>
<br/>
<br/>            19<br/>            (12.9 to 27.1)<br/>
<br/>
<br/>            44.9<br/>            (29.5 to 52.5)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>3.62<br/>(2.44 to 5.28)<br/> <br/> <br/>1.2<br/>(0.75 to 2.42)<br/> <br/> <br/>0.47<br/>(0.23 to 0.77)<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Ages 5 to 11 years</content>
<br/> <br/> Subjects taking carbamazepine,<br/> phenytoin, phenobarbital, or<br/> primidone<sup>a</sup>
<br/> <br/> Subjects taking carbamazepine,<br/> phenytoin, phenobarbital, or<br/> primidone<sup>a</sup> plus valproate<br/> <br/> Subjects taking valproate only<sup>b</sup>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>7<br/> <br/> <br/> <br/>8<br/> <br/> <br/> <br/>3<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>1.6<br/>(1 to 3)<br/> <br/> <br/>3.3<br/>(1 to 6.4)<br/> <br/> <br/>4.5<br/>(3 to 6)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>7<br/>(3.8 to 9.8)<br/> <br/> <br/>19.1<br/>(7 to 31.2)<br/> <br/> <br/>65.8<br/>(50.7 to 73.7)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>2.54<br/>(1.35 to 5.58)<br/> <br/> <br/>0.89<br/>(0.39 to 1.93)<br/> <br/> <br/>0.24<br/>(0.21 to 0.26)<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">
<content stylecode="bold"> Ages 13 to 18 years</content>
<br/> <br/> Subjects taking carbamazepine,<br/> phenytoin, phenobarbital, or<br/> primidone<sup>a</sup>
<br/> <br/> Subjects taking carbamazepine,<br/> phenytoin, phenobarbital, or<br/> primidone<sup>a</sup> plus valproate<br/> <br/> Subjects taking valproate only<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>11<br/> <br/> <br/> <br/>8<br/> <br/> <br/> <br/>4<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>___<sup>c</sup>
<br/>
<br/>
<br/>
<br/>            ___<sup>c</sup>
<br/>
<br/>
<br/>
<br/>            ___<sup>c</sup>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>___<sup>c</sup>
<br/>
<br/>
<br/>
<br/>            ___<sup>c</sup>
<br/>
<br/>
<br/>
<br/>            ___<sup>c</sup>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top"> <br/> <br/>1.3<br/> <br/> <br/>
<br/>            0.5<br/> <br/> <br/> <br/>            0.3<br/>
</td>
</tr>
</tbody>
</table>